Lilly to pay $1.2B for Ventyx and its NLRP3 drugs

FierceBiotechCould engaging the immune system improve AML outcomes?

FierceBiotechWhy AI is changing clinical development

FierceBiotechManaging complexity across biopharma modalities

NINGBO YONGXIN OPTICS CO., LTD.World Microscope Objectives - Market Analysis, Forecast, Size, Trends and Insights - IndexBox

Endpoints News#ADA26: 19% of Phase 3 patients quit Boehringer obesity shot over side effects

IlluminaIllumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch - Yahoo Finance

FierceBiotechADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect

MIURA CO.,LTD.Miura Co., Ltd. 2026 Q4 - Results - Earnings Call Presentation (OTCMKTS:MIURF) 2026-06-06 - Seeking Alpha

10x Genomics News10x Genomics (TXG) Is Up 9.7% After Momentum Rally Despite Weak Fundamentals - What's Changed - simplywall.st

FierceBiotechADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes

Clinical OMICsGLP-1 Drugs Lower Risk of Death by 44% in Obesity and Autoimmune Disease

CellDeep-sea megafauna co-opts microbial energy metabolism genes to withstand ultra-long starvation